Doxorubicin

Author: Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Definition
This section has been translated automatically.

Substance from the group of cytostatic drugs (anthracyclines).

Half-life
This section has been translated automatically.

30–33 h

Indication
This section has been translated automatically.

Lymphomas, leukemias, solid tumors; Kaposi's sarcoma.

Dosage and method of use
This section has been translated automatically.

40-75 mg/m2 KO i.v. every 3-4 weeks Maximum cumulative dose 550 mg/m2 KO.

Notice! Under therapy and up to 3 months afterwards, women and men must practice effective contraception!

Undesirable effects
This section has been translated automatically.

Dermatological complications:

Other:

  • Gastrointestinal disorders
  • Liver damage
  • Hyperuricemia
  • disorders of spermatogenesis and ovulation
  • Disorders of hematopoiesis
  • cardiotoxicity (cardiomyopathy).

Interactions
This section has been translated automatically.

See Table 1.

Contraindication
This section has been translated automatically.

Pregnancy, nursing.

Preparations
This section has been translated automatically.

Adriblastine, DOXO-cell, Doxorubicin, Ribodoxo-L

Literature
This section has been translated automatically.

  1. Lybaek D et al (2006) Pegylated liposomal doxorubicin in the treatment of mycosis fungoides. Acta Derm Venereol 86: 545-547

Tables
This section has been translated automatically.

Main interactions of Doxorubicin

Acetylcysteine

Cardiotoxicity ↓

Anthracyclines

Cardiotoxicity ↑

Antihistamines

Cardiotoxicity ↓

Cyclophosphamide

Cardiotoxicity ↑

Cytarabine

Intestinal necrosis

Digoxin

Cardiotoxicity ↓

Phenobarbital

Doxorubicin effect ↓

Verapamil

Cardiotoxicity ↓

Authors

Last updated on: 29.10.2020